
Stéphane Bolduc

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/804219/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Exosomes Induce Fibroblast Differentiation into Cancer-Associated Fibroblasts through TGFβ Signaling. Molecular Cancer Research, 2018, 16, 1196-1204.	1.5	200
2	Cancer-associated fibroblasts induce epithelial–mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling. BMC Cancer, 2019, 19, 137.	1.1	190
3	Tissue Engineering of Urinary Bladder and Urethra: Advances from Bench to Patients. Scientific World Journal, The, 2013, 2013, 1-13.	0.8	87
4	Anticancer properties of chitosan on human melanoma are cell line dependent. International Journal of Biological Macromolecules, 2015, 72, 370-379.	3.6	84
5	Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder. European Urology, 2016, 70, 9-13.	0.9	78
6	Innovative Human Three-Dimensional Tissue-Engineered Models as an Alternative to Animal Testing. Bioengineering, 2020, 7, 115.	1.6	72
7	<i>In Vitro</i> Reconstruction of an Autologous, Watertight, and Resistant Vesical Equivalent. Tissue Engineering - Part A, 2010, 16, 1539-1548.	1.6	57
8	Mechanical Stimuli-induced Urothelial Differentiation in a Human Tissue-engineered Tubular Genitourinary Graft. European Urology, 2011, 60, 1291-1298.	0.9	56
9	Prospective Open Label Study of Solifenacin for Overactive Bladder in Children. Journal of Urology, 2010, 184, 1668-1673.	0.2	55
10	Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Canadian Urological Association Journal, 2013, 1, 377.	0.3	55
11	In vitro reconstruction of a tissue-engineered endothelialized bladder from a single porcine biopsy. Journal of Pediatric Urology, 2006, 2, 261-270.	0.6	47
12	Double Anticholinergic Therapy for Refractory Overactive Bladder. Journal of Urology, 2009, 182, 2033-2039.	0.2	47
13	Tissue-engineered human 3D model of bladder cancer for invasion study and drug discovery. Biomaterials, 2017, 145, 233-241.	5.7	47
14	Tissue Engineering of a Genitourinary Tubular Tissue Graft Resistant to Suturing and High Internal Pressures. Tissue Engineering - Part A, 2009, 15, 197-202.	1.6	46
15	Dual Therapy for Refractory Overactive Bladder in Children: AÂProspective Open-Label Study. Journal of Urology, 2017, 197, 1158-1163.	0.2	39
16	Factors predicting overall success: a review of 747 microsurgical vasovasostomies. Canadian Urological Association Journal, 2013, 1, 388.	0.3	38
17	Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study. Canadian Urological Association Journal, 2014, 8, 118.	0.3	33
18	An endothelialized urothelial cell-seeded tubular graft for urethral replacement. Canadian Urological Association Journal, 2013, 7, 4.	0.3	32

STéPHANE BOLDUC

#	Article	IF	CITATIONS
19	Bladder substitute reconstructed in a physiological pressure environment. Journal of Pediatric Urology, 2011, 7, 276-282.	0.6	30
20	Adipose-derived stromal cells for the reconstruction of a human vesical equivalent. Journal of Tissue Engineering and Regenerative Medicine, 2015, 9, E135-E143.	1.3	28
21	Overactive bladder in children. Canadian Urological Association Journal, 2017, 11, 74.	0.3	28
22	Human Organ-Specific 3D Cancer Models Produced by the Stromal Self-Assembly Method of Tissue Engineering for the Study of Solid Tumors. BioMed Research International, 2020, 2020, 1-23.	0.9	28
23	Inexpensive production of near-native engineered stromas. Journal of Tissue Engineering and Regenerative Medicine, 2017, 11, 1377-1389.	1.3	27
24	Engineering Tissues without the Use of a Synthetic Scaffold: A Twenty-Year History of the Self-Assembly Method. BioMed Research International, 2018, 2018, 1-13.	0.9	22
25	Lysophosphatidic acid enhances collagen deposition and matrix thickening in engineered tissue. Journal of Tissue Engineering and Regenerative Medicine, 2015, 9, E65-E75.	1.3	21
26	Learning curve for TIP urethroplasty: A single-surgeon experience. Canadian Urological Association Journal, 2013, 7, 789.	0.3	19
27	Prospective Study of Polydimethylsiloxane vs Dextranomer/Hyaluronic Acid Injection for Treatment of Vesicoureteral Reflux. Journal of Urology, 2014, 192, 1794-1800.	0.2	19
28	Novel three-dimensional autologous tissue-engineered vaginal tissues using the self-assembly technique. Translational Research, 2017, 180, 22-36.	2.2	19
29	Vesicoureteral reflux: From prophylaxis to surgery. Canadian Urological Association Journal, 2017, 11, 13.	0.3	19
30	Prevascularized Tissue-Engineered Human Vaginal Mucosa: In Vitro Optimization and In Vivo Validation. Tissue Engineering - Part A, 2020, 26, 811-822.	1.6	19
31	Double anticholinergic therapy for refractory neurogenic and non-neurogenic detrusor overactivity in children: Long-term results of a prospective open-label study. Canadian Urological Association Journal, 2014, 8, 175.	0.3	18
32	Endocrine-disrupting effects of bisphenols on urological cancers. Environmental Research, 2021, 195, 110485.	3.7	18
33	Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive Bladder. Journal of Urology, 2017, 198, 928-936.	0.2	17
34	Conditioned medium produced by fibroblasts cultured in low oxygen pressure allows the formation of highly structured capillary-like networks in fibrin gels. Scientific Reports, 2020, 10, 9291.	1.6	17
35	Demonstration of the direct impact of ketamine on urothelium using a tissue engineered bladder model. Canadian Urological Association Journal, 2015, 9, 613.	0.3	16
36	Urothelial cell expansion and differentiation are improved by exposure to hypoxia. Journal of Tissue Engineering and Regenerative Medicine, 2017, 11, 3090-3099.	1.3	16

STéPHANE BOLDUC

#	Article	IF	CITATIONS
37	An endothelialized urothelial cell-seeded tubular graft for urethral replacement. Canadian Urological Association Journal, 2013, 7, E4-9.	0.3	14
38	Production of an Optimized Tissue-Engineered Pig Connective Tissue for the Reconstruction of the Urinary Tract. Tissue Engineering - Part A, 2011, 17, 1625-1633.	1.6	13
39	Biological Assessment of Zn–Based Absorbable Metals for Ureteral Stent Applications. Materials, 2019, 12, 3325.	1.3	12
40	A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine. Canadian Urological Association Journal, 2020, 14, 319-321.	0.3	11
41	Dimercaptosuccinic acid scintigraphy vs. ultrasound for renal parenchymal defects in children. Canadian Urological Association Journal, 2017, 11, 260-4.	0.3	10
42	Use of a magnetic double J stent in pediatric patients: A case–control study at two Canadian pediatric centers. Journal of Pediatric Surgery, 2020, 55, 486-489.	0.8	10
43	Bisphenol A Alters the Energy Metabolism of Stromal Cells and Could Promote Bladder Cancer Progression. Cancers, 2021, 13, 5461.	1.7	10
44	Collagen hollow structure for bladder tissue engineering. Materials Science and Engineering C, 2019, 102, 228-237.	3.8	9
45	Genitourinary Tissue Engineering: Reconstruction and Research Models. Bioengineering, 2021, 8, 99.	1.6	9
46	Adherence to antimuscarinics in children with overactive bladder. Paediatrics and Child Health, 2017, 22, 255-258.	0.3	8
47	Reconstruction of Vascular and Urologic Tubular Grafts by Tissue Engineering. Processes, 2021, 9, 513.	1.3	8
48	Clinical challenges in tissue-engineered urethral reconstruction. Translational Andrology and Urology, 2016, 5, 267-270.	0.6	8
49	Efficacy of dextranomer hyaluronic acid and polyacrylamide hydrogel in endoscopic treatment of vesicoureteral reflux: A comparative study. Canadian Urological Association Journal, 2015, 9, 202.	0.3	8
50	Intrascrotal extratesticular schwannoma: A first pediatric case. Canadian Urological Association Journal, 2014, 8, 279.	0.3	7
51	Optimization of the current self-assembled urinary bladder model: Organ-specific stroma and smooth muscle inclusion. Canadian Urological Association Journal, 2015, 9, 599.	0.3	7
52	A randomized, crossover trial comparing the efficacy and safety of fesoterodine and extended-release oxybutynin in children with overactive bladder with 12-month extension on fesoterodine: The FOXY study. Canadian Urological Association Journal, 2020, 14, 192-198.	0.3	7
53	Immunocompetent Human 3D Organ-Specific Hormone-Responding Vaginal Mucosa Model of HIV-1 Infection. Tissue Engineering - Part C: Methods, 2021, 27, 152-166.	1.1	6
54	Early detection of prostate cancer local recurrence by urinary prostate-specific antigen. Canadian Urological Association Journal, 2013, 3, 213.	0.3	5

STéPHANE BOLDUC

#	Article	IF	CITATIONS
55	Heat-Inactivation of Fetal and Newborn Sera Did Not Impair the Expansion and Scaffold Engineering Potentials of Fibroblasts. Bioengineering, 2021, 8, 184.	1.6	5
56	Strategies to Reconstruct a Functional Urethral Substitute by Self-assembly Method. Procedia Engineering, 2013, 59, 193-200.	1.2	4
57	Origin of Serum Affects Quality of Engineered Tissues Produced by the Self-Assembly Approach. Scientifica, 2016, 2016, 1-10.	0.6	4
58	How far are they coming from?. Canadian Urological Association Journal, 2019, 13, 391-394.	0.3	2
59	Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children. Expert Opinion on Pharmacotherapy, 2022, , 1-12.	0.9	2
60	Maintenance of bladder urothelia integrity and successful urothelialization of various tissue-engineered mesenchymes in vitro. In Vitro Cellular and Developmental Biology - Animal, 2015, 51, 922-931.	0.7	1
61	Confirmed testicular mass on ultrasound: no evidence on histology Report of two cases in teenagers. Canadian Urological Association Journal, 2019, 14, E101-E103.	0.3	0
62	Case – Bilateral and recurrent pediatric cystic nephroma associated with DICER1 mutation. Canadian Urological Association Journal, 2020, 15, E290-E292.	0.3	0
63	Bladder cancer cell lines adapt their aggressiveness profile to oxygen tension. Oncology Letters, 2022, 24, .	0.8	Ο